



Lotus Eye Hospital And Institute Limited

CIN No. : L85110TZ1997PLC007783

770/12, Avinashi Road, Civil Aerodrome Post, Coimbatore - 641 014.

Tel : 0422 - 4229900, 4229999 Fax : 0422 - 4229933



R.S. PURAM

155B, East Periasamy Road, Near Chinthamani,
North Coimbatore, R.S. Puram,
Coimbatore - 2. Phone : 0422 - 4239900, 4239999

METTUPPALAYAM

No. 28, Coimbatore Main Rd,
Opp. Bus Stand, MTP - 634 301.
Phone : 04254 - 223223, 224224

TIRUPUR

Tiruppur : Near Santha Pettai Bus Stop,
Thennampalayam, Palladam Road,
Tiruppur-641 604.
Tel. : 0421 - 4346060, 4219999

SALEM

86, Brindhavan Road, Fairlands
Salem - 636 004.
Ph. : 0427 - 4219900, 4219999

E-mail : info@lotuseye.org

Website : www.lotuseye.org

November 14, 2023

BSE Limited PhirozeJeejeebhoy Towers Dalal Street Mumbai- 400001 Scrip Code: 532998	National Stock Exchange of India Limited 5th Floor, Exchange Plaza Bandra (East) Mumbai – 400 051 Scrip Code: LOTUSEYE
--	---

Dear Sir/Madam

Sub: Outcome of Board Meeting held on November 14th 2023

In terms of Regulation 30 read with Part A Schedule III of SEBI (Listing Obligation and Disclosure Requirements) Regulations 2015, we wish to inform you that the Board of Directors of the Company at its meeting held on November 14, 2023 has transacted the following business:

- 1) Approved unaudited standalone results for the quarter and period ended September 30th, 2023;

The Board meeting commenced by 04:45 PM and ended by 06:30 PM

We request you to please take the same on your record.

Yours Faithfully
For Lotus Eye Hospital and Institute Limited

M Achuth Menon
Company secretary & Compliance Officer
Membership No – A63980

Kochi

533/33A-33F, Tejas Tower
SA Road, Kadavanthara,
Kochi, Kerala - 682 020.
Tel. : 0484 - 2322333, 2322444

Always for you

Kochi

229A, Kurisingal House
Mulanthuruty Post
Kochi, Kerala - 682 314.
Tel. : 0484 - 2743191, 2743121



Lotus Eye Hospital and Institute Limited

CIN: L85110TZ1997PLC007783

Registered office: 770/12, Avinashi road, Aerodrome post, Coimbatore 641 014

Phone no: 0422-4229900, Fax: 0422-4229933, E-mail: companysecretary@lotuseye.org, Website: www.lotuseye.org

Statement of Un-audited Financial Results for the Half year/Quarter ended September 30, 2023


Sr. No.	Particulars	Quarter ended			Half year ended		Year ended
		30-Sep-23 (Un-audited)	30-Jun-23 (Un-audited)	30-Sep-22 (Un-audited)	30-Sep-23 (Un-audited)	30-Sep-22 (Un-audited)	31-Mar-23 (Audited)
	Income:						
I.	Revenue from operations	1,272.96	1,256.73	1,186.41	2,529.68	2,373.84	4,704.39
II.	Other income	26.98	28.60	23.11	55.58	46.99	114.55
III.	Total income (I+II)	1,299.94	1,285.33	1,209.52	2,585.26	2,420.83	4,818.94
	Expenses:						
IV.	(a) Cost of materials consumed	228.50	223.07	211.67	451.56	420.88	834.96
	(b) Purchase of stock-in-trade	201.15	175.05	181.95	376.20	363.51	693.39
	(c) Changes in inventories	(12.52)	(6.74)	(9.67)	(19.26)	(27.11)	(30.33)
	(d) Service expenses	193.90	191.49	174.70	385.39	341.16	700.46
	(e) Employee benefit expense	245.69	225.18	219.88	470.88	427.18	888.05
	(f) Finance costs	1.33	1.63	2.60	2.96	5.64	9.76
	(g) Depreciation and amortization expense	89.37	73.06	75.13	162.44	143.20	298.05
	(h) Other expenses	234.84	210.64	232.64	445.48	440.38	859.21
	Total expenses (IV)	1,182.26	1,093.38	1,088.90	2,275.65	2,114.84	4,253.55
V.	Profit/(loss) before exceptional items and tax (III-IV)	117.68	191.95	120.62	309.61	305.99	565.39
VI.	Exceptional Items	0.82	0.56	(0.14)	1.38	(0.14)	(0.18)
VII.	Profit/(loss) before tax (V+VI)	118.50	192.51	120.48	310.99	305.85	565.21
VIII.	Tax expenses						
	(a) Current tax	31.85	51.26	28.26	83.11	70.76	141.01
	(b) Deferred tax	1.66	2.88	2.19	4.54	7.93	16.45
	Total tax expense (VIII)	33.51	54.14	30.45	87.65	78.69	157.46
IX.	Net profit/(loss) for the period (VII-VIII)	84.99	138.37	90.03	223.34	227.16	407.75
X.	Other comprehensive income, net of income tax						
	A. Items that will not be reclassified to profit or loss						
	- Remeasurement of post-employment defined benefit plans	(2.00)	(2.00)	1.00	(4.00)	2.00	(9.27)
	- Income tax on the above item	0.56	0.56	(0.28)	1.11	(0.55)	2.58
	B. Items that will be reclassified to profit or loss	-	-	-	-	-	-
	Total other comprehensive income, net of income tax (X)	(1.44)	(1.44)	0.72	(2.89)	1.45	(6.69)
XI.	Total comprehensive income for the period (IX + X)	83.55	136.93	90.75	220.45	228.61	401.06
XII.	Paid-up equity share capital (face value of Rs. 10/- each)	2,079.63	2,079.63	2,079.63	2,079.63	2,079.63	2,079.63
XIII.	Earning per equity share: (of Rs. 10/-) (Not annualised) :						
	(1) Basic (in Rs.)	0.41	0.67	0.43	1.07	1.09	1.96
	(2) Diluted (in Rs.)	0.41	0.67	0.43	1.07	1.09	1.96

Notes:

- 1 The above results have been reviewed by the Audit committee and approved by the Board of Directors at their meeting held on November 14, 2023. The above results has also been subjected to limited review by statutory auditors of the company.
- 2 Exceptional items represent the profit/(loss) on sale of property, plant & equipment.
- 3 Figures of the previous periods have been regrouped and reclassified to confirm to the classification of current period, wherever necessary.

Coimbatore,
November 14, 2023.

For Lotus Eye Hospital & Institute Limited


Ms. S. SANGEETHA
 Managing Director - DIN : 01859252



Lotus Eye Hospital and Institute Limited

CIN: L85110TZ1997PLC007783

Registered office: 770/12, Avinashi road, Aerodrome post, Coimbatore 641 014


Phone no: 0422-4229900, Fax: 0422-4229933, E-mail: companysecretary@lotuseye.org, Website: www.lotuseye.org

Statement of Assets & Liabilities

Particulars	(Rs. in lakhs)	
	As at Sept 30, 2023 (Unaudited)	As at March 31, 2023 (Audited)
Assets		
1. Non-current assets		
(a) Property, plant and equipment	4,651.90	4,347.01
(b) Right of use asset	38.32	60.45
(c) Intangible assets	8.80	10.15
(d) Financial assets		
(i) Other financial assets	-	95.00
(e) Deferred tax assets (net)	35.01	38.44
(f) Other non-current assets	306.11	296.74
Total Non-current assets (A)	5,040.14	4,847.79
2. Current assets		
(a) Inventories	310.20	279.06
(b) Financial assets		
(i) Trade receivables	124.88	117.21
(ii) Cash and cash equivalents	145.76	360.30
(iii) Bank balances other than above	799.61	481.10
(c) Other current assets	260.83	233.34
Total Current assets (B)	1,641.28	1,471.01
Total Assets (A + B)	6,681.42	6,318.80
Equity and Liabilities		
1. Equity		
(a) Equity share capital	2,079.63	2,079.63
(b) Other equity	3,794.78	3,678.31
Total Equity (C)	5,874.41	5,757.94
2. Liabilities		
Non-current liabilities		
(a) Financial liabilities		
(i) Trade payables		
(1) Total outstanding dues of creditors other than micro enterprises and small enterprises.	7.28	-
(ii) Lease Liabilities	10.01	19.21
(b) Other non-current liabilities	22.35	22.49
Total Non-current liabilities (D)	39.64	41.70
Current liabilities		
(a) Financial liabilities		
(i) Trade payables		
(1) Total outstanding dues of micro enterprises and small enterprises.	31.48	22.32
(2) Total outstanding dues of creditors other than micro enterprises and small enterprises.	423.80	292.67
(ii) Lease Liabilities	33.73	47.83
(b) Other current liabilities	278.36	156.34
Total Current liabilities (E)	767.37	519.16
Total Liabilities (D+E)	807.01	560.86
Total Equity and Liabilities (C+D+E)	6,681.42	6,318.80

Coimbatore,
November 14, 2023.

For Lotus Eye Hospital & Institute Limited


Ms. S. SANGEETHA
Managing Director - DIN : 01859252



Lotus Eye Hospital and Institute Limited

CIN: L85110TZ1997PLC007783

Registered office: 770/12, Avinashi road, Aerodrome post, Coimbatore 641 014

Phone no: 0422-4229900, Fax: 0422-4229933, E-mail: companysecretary@lotuseye.org, Website: www.lotuseye.org

Statement of Cash Flows

Particulars	(Rs. in lakhs)	
	For the period ended 30 September, 2023 (Unaudited)	For the period ended 30 September, 2022 (Unaudited)
A. Cash flows from operating activities		
Profit before tax and exceptional item	309.61	305.99
<i>Adjustments:</i>		
Depreciation and amortisation	162.44	143.20
Interest income	(26.45)	(17.96)
Rental income	(21.98)	(21.30)
Finance costs	2.96	5.64
Operating cash flow before working capital changes	426.58	415.57
Change in operating assets & liabilities :		
Inventories	(31.14)	(32.57)
Trade receivables	(7.67)	(30.91)
Other assets (current and non-current)	(36.86)	(24.20)
Trade payables	147.57	6.87
Provisions	(4.00)	(45.00)
Other liabilities (current and non-current)	17.90	80.26
Cash generated from operating activities	512.38	370.02
Taxes paid (Net)	(83.11)	(70.76)
Net cash generated from operating activities (A)	429.27	299.26
B. Cash flows from investing activities		
Purchase of property, plant and equipment	(444.83)	(171.65)
Proceeds from the sale of property, plant and equipment	2.37	0.22
Interest income	26.45	17.96
Rental income	21.98	21.30
Net cash generated from / (used in) investing activities (B)	(394.03)	(132.17)
C. Cash flows from financing activities		
Finance costs	(2.96)	(5.64)
Dividend paid	(103.98)	(103.98)
(Payment of) / Increase in lease liabilities	(23.30)	(34.40)
Net cash (used in) / generated from financing activities (C)	(130.24)	(144.02)
Net increase / (decrease) in cash and cash equivalents (A+B+C)	(95.00)	23.07
Cash and cash equivalents at the beginning of the year	928.05	879.30
Cash and equivalents at the end of the year	833.05	902.37
Cash on hand	9.83	9.70
Balance with banks	823.22	892.67

Note:

1. Cash and bank balances do not include dividend payable (including unclaimed dividend) Rs. 112.32 Lakhs as on September 30, 2023 and Rs. 109.42 Lakhs as on September 30, 2022.

Coimbatore,
November 14, 2023.

For Lotus Eye Hospital & Institute Limited


Ms. S. SANGEETHA
Managing Director - DIN : 01859252

ANBARASU & JALAPATHI

CHARTERED ACCOUNTANTS



To
The Board of Directors,
Lotus Eye Hospital and Institute Limited,
Coimbatore.

Limited review report for the Quarter/Half year ended September 30, 2023

1. We have reviewed the accompanying statement of unaudited financial results of Lotus Eye Hospital and Institute Limited ("the Company") for the quarter/half year ended September 30, 2023, being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended.
2. This statement which is the responsibility of the Company's management and approved by the Board of Directors at their meeting on November 14, 2023, has been prepared in accordance with the recognition and measurement principles laid down in the Indian Accounting Standard 34 "Interim Financial Reporting" ("Ind AS 34"), prescribed under Section 133 of the Companies Act, 2013 read with relevant rules issued thereunder and other accounting principles generally accepted in India. Our responsibility is to issue a report on these financial statements based on our review.
3. We conducted our review in accordance with the Standard on Review Engagement (SRE) 2410, 'Review of Interim Financial Information Performed by the Independent Auditor of the Entity' issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the financial statements are free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as stated above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with the aforesaid Indian Accounting Standards and other recognized accounting practices and policies, have not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as amended, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Coimbatore,
November 14, 2023.

For Anbarasu & Jalapathi
Chartered Accountants
Firm Registration No.: 010795S

CA. S. Anbarasu
Partner
Membership No.: 212299
UDIN: 23212299B61V2YV2660

30 C, ALAGESAN ROAD,
SAIBABA COLONY, COIMBATORE - 641 011.

0422 - 4385673

98422 96673, 98428 96673

VCV COMPLEX, FIRST FLOOR,
169-1, MYSORE TRUNK ROAD,
SATHYAMANGALAM - 638 402.

98427 46673

INFO@ANBUJALA.CA

WWW.ANBUJALA.CA